Article
Cell Biology
Davide Perico, Ying Tong, Lichao Chen, Shoji Imamichi, Yu Sanada, Masamichi Ishiai, Minoru Suzuki, Mitsuko Masutani, Pierluigi Mauri
Summary: Boron neutron capture therapy (BNCT) is a selective radiotherapy that uses nuclear reactions to induce cell death in cancer cells. Proteomic analysis of extracellular vesicles (EVs) treated with BNCT identified proteins associated with apoptosis, DNA repair, and inflammatory response. The results highlight the potential of proteomics in identifying biomarkers and understanding the mechanisms of BNCT.
Article
Cell Biology
Magdalena Surman, Sylwia Kedracka-Krok, Magdalena Wilczak, Piotr Rybczynski, Urszula Jankowska, Malgorzata Przybylo
Summary: Proteins carried by tumor-derived vesicles play an important role in cancer progression and have potential as diagnostic markers. This study compared protein content between vesicles released by normal and cancerous thyroid cells, and investigated the effects of these vesicles on other cells. The results showed that cancer-derived vesicles contained more proteins, some of which were unique and may be useful for thyroid cancer diagnosis and treatment. Additionally, these vesicles were found to promote cell proliferation and migration.
Article
Medicine, General & Internal
Adam C. Swensen, Jingtang He, Alexander C. Fang, Yinyin Ye, Carrie D. Nicora, Tujin Shi, Alvin Y. Liu, Tara K. Sigdel, Minnie M. Sarwal, Wei-Jun Qian
Summary: Urine proteins can be used as biomarkers for diagnosing and monitoring diseases, and a comprehensive urine proteome database can aid in the discovery of potential biomarkers. This study identified a wide range of proteins from urine samples of different disease conditions, with many unique proteins that may represent disease-associated proteins. The data provides valuable information for future discovery and validation studies of urine protein biomarkers for various diseases.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Song Wang, Zhengchao Zhang, Lele Miao, Jiaxing Zhang, Futian Tang, Muzhou Teng, Yumin Li
Summary: Boron Neutron Capture Therapy (BNCT) is a new binary radiation therapy that uses neutron capture reaction to kill tumor cells. It has been included in the clinical backup program for the treatment of glioma, melanoma, and other diseases. However, the key challenge of BNCT lies in developing more efficient boron delivery agents to improve targeting and selectivity.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biology
Yu Sanada, Takushi Takata, Hiroki Tanaka, Yoshinori Sakurai, Tsubasa Watanabe, Minoru Suzuki, Shin-ichiro Masunaga
Summary: The study revealed that hypoxia may reduce the effectiveness of boron neutron capture therapy (BNCT) with BPA in murine squamous cell carcinoma cells, while disruption of Hif-1 alpha increased sensitivity to BNCT.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2021)
Article
Oncology
Chun-Hsiang Chang, Chi-Jui Chen, Ching-Fang Yu, Hui-Yu Tsai, Fang-Hsin Chen, Chi-Shiun Chiang
Summary: The study aimed to investigate the impact of boron neutron capture therapy (BNCT) on myeloid-derived suppressive cells (MDSCs) in head and neck squamous cell carcinoma (HNSCC) and explore the potential for MDSCs depletion combined with BNCT to reactivate antitumor immunity. The results showed that after BNCT treatment, there were temporary and persistent increases of moncytic-MDSCs (M-MDSCs) in the tumor microenvironment and peripheral blood. Inhibition of CSF-1 receptor hindered M-MDSCs infiltration, prolonged survival, and activated tumor immunity.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Katsumi Hirose, Akiyoshi Konno, Junichi Hiratsuka, Seiichi Yoshimoto, Takahiro Kato, Koji Ono, Naoki Otsuki, Jun Hatazawa, Hiroki Tanaka, Kanako Takayama, Hitoshi Wada, Motohisa Suzuki, Mariko Sato, Hisashi Yamaguchi, Ichiro Seto, Yuji Ueki, Susumu Iketani, Shigeki Imai, Tatsuya Nakamura, Takashi Ono, Hiromasa Endo, Yusuke Azami, Yasuhiro Kikuchi, Masao Murakami, Yoshihiro Takai
Summary: The study aimed to evaluate the efficacy and safety of cyclotron-based BNCT with borofalan for treating head and neck cancer, demonstrating promising treatment outcomes for patients with R-SCC or R/LA-nSCC.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Austin Baker, Patrick Tassone, Laura M. Dooley, Tabitha I. Galloway, Robert P. Zitsch III
Summary: A retrospective analysis compared the rates of post-operative chyle leak between patients with squamous cell carcinoma (SCC) and patients with papillary thyroid carcinoma (PTC) who underwent therapeutic neck dissection. The results showed that chyle leak mainly occurred in PTC patients, and high-volume leaks requiring operative intervention were also only observed in PTC patients.
Article
Oncology
Yoelsis Garcia-Mayea, Lisandra Benitez-Alvarez, Almudena Sanchez-Garcia, Marina Bataller, Osmel Companioni, Cristina Mir, Sergi Benavente, Juan Lorente, Nuria Canela, Ceres Fernandez-Rozadilla, Angel Carracedo, Matilde E. LLeonart
Summary: Treatment failures in HNSCC patients are often caused by the presence of resistant cells. This study used RNA sequencing and proteomics to understand the molecular mechanisms of chemoresistance in HNSCC and identified a potential protein target, MAGEB2, for sensitizing resistant patients to therapy.
Review
Oncology
Andrea Monti Hughes, Naonori Hu
Summary: Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy that combines boron accumulation in tumors and neutron irradiation. Utilizing hospital-based accelerators as neutron sources, instead of nuclear reactors, in BNCT clinical trials opens up possibilities for more trials and randomized studies. The implementation of new boron compounds and strategies, along with communication among healthcare professionals, will optimize BNCT for cancer patients.
Article
Medicine, General & Internal
Hua Fan, Xue Li, Zhong-Wu Li, Nai-Ren Zheng, Li-Hua Cao, Zong-Chao Liu, Ming-Wei Liu, Kai Li, Wen-Hui Wu, Zhe-Xuan Li, Tong Zhou, Yang Zhang, Wei-Dong Liu, Lan-Fu Zhang, Wei-Cheng You, Yi Wang, Jianmin Wu, Kai-Feng Pan, Jun Qin, Wen-Qing Li
Summary: This study identified urine proteomic signatures and protein biomarkers that can predict the progression of gastric lesions and the risk of gastric cancer. These biomarkers have the potential for translation significance in defining high-risk populations for gastric cancer and early detection.
Article
Biochemistry & Molecular Biology
Hicham Benabdelkamel, Afshan Masood, Aishah A. Ekhzaimy, Assim A. Alfadda
Summary: This study characterized the urinary proteome of patients with hyperthyroidism using an untargeted proteomic approach, revealing differences in protein abundance before and after treatment. The identified proteins are involved in regulating cellular metabolism, transport, and acute phase response processes. Bioinformatic analysis indicated dysregulation of pathways associated with cellular compromise, inflammatory response, and identified central nodes such as the APP and AKT signaling pathways.
Article
Biochemistry & Molecular Biology
Heba Badr, Ron Blutrich, Kaitlin Chan, Jiefei Tong, Paul Taylor, Wen Zhang, Ran Kafri, Hannes L. Rost, Ming-Sound Tsao, Michael F. Moran
Summary: Proteome analysis revealed co-expressed upregulated metabolism proteins highly conserved between primary NSCLC and patient-derived xenograft tumors. The encoded genes of these proteins are associated with the survival of NSCLC patients, suggesting their role in driving NSCLC through metabolic processes.
JOURNAL OF MOLECULAR BIOLOGY
(2022)
Article
Oncology
Alicja Gluszko, Miroslaw J. Szczepanski, Theresa L. Whiteside, Torsten E. Reichert, Jacek Siewiera, Nils Ludwig
Summary: Tissue hypoxia is a common feature in HNSCC, leading to alterations in tumor cells. The study found that sEVs released by HNSCC cells under hypoxic conditions have a unique protein composition, which can potentially serve as biomarkers for different degrees of tissue hypoxia and as a resource for anti-angiogenic therapies.
Article
Biology
Andrea Monti Hughes, Jessica A. Goldfinger, Monica A. Palmieri, Paula Ramos, Iara S. Santa Cruz, Luciana De Leo, Marcela A. Garabalino, Silvia Thorp, Paula Curotto, Emiliano C. C. Pozzi, Kazuki Kawai, Shinichi Sato, Maria E. Itoiz, Veronica A. Trivillin, Juan S. Guidobono, Hiroyuki Nakamura, Amanda E. Schwint
Summary: This study evaluated the distribution and therapeutic effect of MID:BSA in a hamster cheek pouch oral cancer model, demonstrating that the 15 mg B/kg dose reached therapeutically useful boron concentration values in the tumor and was well-tolerated, while the 30 mg B/kg dose induced high toxicity.
Article
Biology
Dario Di Silvestre, Giulia Passignani, Rossana Rossi, Marina Ciuffo, Massimo Turina, Gianpiero Vigani, Pier Luigi Mauri
Summary: A newly discovered plant mitovirus activates metabolic processes in quinoa to help them withstand drought, providing a new perspective for breeding crop plants. The study found changes in mitochondrial protein expression in infected plants, with up-regulation of functional modules involved in stress response and redox homeostasis, suggesting a potential mechanism for the observed higher tolerance to drought in infected plants. Further in-depth functional studies are needed to establish a causative link.
Article
Oncology
J. Herault, A. Gerard, A. Carnicer, D. Aloi, M-L Peyrichon, C. Barnel, M. Vidal, G. Angellier, D. Fayaud, J-C Grini, A. Giusto, C. Armando, G. Donadey, M. Cabannes, S. Dumas, Y. Payan, J-F Di Carlo, C. Salicis, J-M Bergerot, M. Rolion, R. Trimaud, P. Hofverberg, P. Mandrillon, W. Sauerwein, J. Thariat
Summary: This article introduces the application of proton therapy in the treatment of ocular tumors, including technical aspects, planning, and delivery processes. Clinical studies have shown that proton therapy can achieve excellent tumor control and functional preservation, with limited toxicities.
CANCER RADIOTHERAPIE
(2022)
Article
Oncology
M. L. Peyrichon, M. Vidal, C. Barnel, W. Sauerwein, A. Carnicer, G. Angellier, T. M. Mathis, K. K. Mishra, J. Thariat, J. Herault, J. Herault
Summary: The study assessed the performances of ocular proton therapy compared to other radiotherapy techniques and found that ocular proton therapy showed better precision, shorter treatment delivery time, better dose homogeneity, and reduced maximal/mean doses to critical ocular structures compared to other external beam radiation modalities.
CANCER RADIOTHERAPIE
(2022)
Article
Oncology
Davide Perico, Dario Di Silvestre, Shoji Imamichi, Yu Sanada, Mitsuko Masutani, Pier Luigi Mauri
Summary: Systems biology approach, particularly proteomics, plays a crucial role in the study and application of complex therapies like Boron Neutron Capture Therapy (BNCT). Proteomics provides insights into the mechanisms and effects of BNCT, identifies potential biomarkers, and contributes to the development of new boron carriers for optimized treatment.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2023)
Article
Oncology
Wolfgang A. G. Sauerwein
Summary: Uniformity in definitions and terminology is needed for reporting in order to compare and aggregate clinical outcomes data across trials. The absence of a standard for reporting dose in boron neutron capture therapy (BNCT) has led to confusion and an unsatisfactory reporting system. A suggestion is made to report input parameters instead of results of calculations, regardless of the model used.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2023)
Article
Oncology
Wolfgang A. G. Sauerwein, Miha Ulcar
Summary: In April 2022, the National Cancer Institute of the United States hosted a seminar on boron neutron capture therapy (BNCT). This article summarizes a presentation from the event, highlighting the global efforts to make BNCT available for patient treatments. The overview demonstrates the active involvement in various areas necessary for BNCT, with an expected increase in BNCT centers and the introduction of new drugs in the coming years. However, creating efficient clinical networks for timely and high-quality prospective clinical trials will be a major challenge for stakeholders.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2023)
Article
Oncology
Elia Bari, Francesca Ferrera, Tiziana Altosole, Sara Perteghella, Pierluigi Mauri, Rossana Rossi, Giulia Passignani, Luca Mastracci, Martina Galati, Giuseppina Iliana Astone, Maddalena Mastrogiacomo, Patrizio Castagnola, Daniela Fenoglio, Dario Di Silvestre, Maria Luisa Torre, Gilberto Filaci
Summary: By using silk fibroin nanoparticles as carriers, researchers found that they can promote the uptake of non-tumor antigens by tumor cells, thus generating an immune response against the tumor, which can enhance the effectiveness of immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Paul T. Finger, Robert Stewart, Mark J. Rivard, Raymond J. Beers, Jacob Kamen, Shyam Lama, Kimberly J. Chin, Kyle Mohney, Toby S. Welles, Wolfgang A. G. Sauerwein, Kenneth Rosenzweig
Summary: This study investigates the application of high-dose-rate (HDR) yttrium-90 (Y-90) brachytherapy in medical physicists, radiation oncologists, and ophthalmic surgeons. The dose calibration and target delineation methods were established to evaluate radiation safety. The results demonstrate the feasibility and effectiveness of HDR Y-90 brachytherapy in clinical practice.
Article
Oncology
Andrea Wittig, Wolfgang A. G. Sauerwein
Summary: Boron neutron capture therapy (BNCT) involves infusing cancer patients with boron-loaded compounds and irradiating them with neutrons. This treatment effectively kills tumor cells while sparing healthy tissue. The challenge lies in designing clinical trials for timely and safe implementation of BNCT. To address this, a methodological framework is proposed for a systematic, coordinated, internationally accepted, and evidence-based approach.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2023)
Article
Cell Biology
Lara Toffali, Beatrice D'Ulivo, Cinzia Giagulli, Alessio Montresor, Elena Zenaro, Massimo Delledonne, Marzia Rossato, Barbara Iadarola, Andrea Sbarbati, Paolo Bernardi, Gabriele Angelini, Barbara Rossi, Nicola Lopez, Wolfgang A. Linke, Andreas Unger, Dario Di Silvestre, Louise Benazzi, Antonella De Palma, Sara Motta, Gabriela Constantin, Pierluigi Mauri, Carlo Laudanna
Summary: Response to multiple microenvironmental cues and resilience to mechanical stress are essential features of trafficking leukocytes. Titin (TTN) plays an unexpected role in the regulation of mechanisms of lymphocyte trafficking. It governs the morphogenesis of plasma membrane microvilli, controls chemotaxis and integrin activation, and ensures T lymphocyte survival in the blood stream. LTTN1 is a critical and versatile housekeeping regulator of T lymphocyte trafficking.
Article
Cell Biology
Davide Perico, Ying Tong, Lichao Chen, Shoji Imamichi, Yu Sanada, Masamichi Ishiai, Minoru Suzuki, Mitsuko Masutani, Pierluigi Mauri
Summary: Boron neutron capture therapy (BNCT) is a selective radiotherapy that uses nuclear reactions to induce cell death in cancer cells. Proteomic analysis of extracellular vesicles (EVs) treated with BNCT identified proteins associated with apoptosis, DNA repair, and inflammatory response. The results highlight the potential of proteomics in identifying biomarkers and understanding the mechanisms of BNCT.
Article
Oncology
Saniya Arfin, Dhruv Kumar, Andrea Lomagno, Pietro Luigi Mauri, Dario Di Silvestre
Summary: This study reveals gene-miRNA interactions and topological biomarkers driving the development of head and neck squamous cell carcinoma (HNSCC) through comprehensive evaluation of gene and miRNA profiles. The molecular interactions activate genes promoting cell cycle and proliferation, and inactivate suppressive genes. Genes including VEGFA, EMP1, PPL, KRAS, MET, TP53, MMPs, and HOXs, and miRNAs including mir-6728 and mir-99a emerge as key players in HNSCC tumorigenesis.
Article
Oncology
Lorenzo Magrassi, Francesca Brambilla, Raffaello Vigano, Dario Di Silvestre, Louise Benazzi, Giuseppe Bellantoni, Gian Marco Danesino, Sergio Comincini, Pierluigi Mauri
Summary: Cystic formation in human primary brain tumors is a relatively rare event that varies depending on the histotype of the tumor. The composition of cystic fluid has been characterized in tumor resection samples, but there is no information on the evolution of cystic content. The proteome of cystic fluid obtained from different time points in the same tumor remained stable, and there are tumor-specific pathways that contribute to tumor-host interactions.
